Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines
- PMID: 35371426
- PMCID: "VSports最新版本" PMC8969875
- DOI: "VSports在线直播" 10.4081/dr.2022.9454
Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines (V体育ios版)
"VSports最新版本" Abstract
Psoriasis is an inflammatory skin disease with a chronic-relapsing course. It is estimated that the prevalence in Italy is 3%. An adequate model of taking care of the patient with psoriasis allows the patient to benefit from the most suitable treatment option for his health needs. In this position statement the observations, criticalities and proposals for improvement of the Pso-Path Working Group, composed by health economists, clinicians and patients, on the diagnostic-therapeutic pathway of the patient with psoriasis have been collected. In particular, the deviation of clinical practice from the current Guidelines for the management of patients with psoriasis, which recommend the use of biologic drugs in case of non-response, intolerance or contraindication to Methotrexate or Cyclosporine, was evaluated. A Working Group was convened whose participants were asked to express their thoughts on the diagnostic and therapeutic pathway of the patient with psoriasis, bringing out critical elements and proposals for improvement, based on their experiences. This position statement summarizes the experiences and consensus between clinicians and patients on actions to optimize the management of patients with psoriasis undergoing biological treatment. Compared to the epidemiological data currently available, it is believed that only a small percentage of patients with psoriasis are treated with systemic drugs. The perception of clinicians, according to their experience, confirms the data emerging from the National Report "National Observatory on the Use of Medicines" (Osmed) compiled by AIFA in 2015, according to which more than 77% of patients with psoriasis are started to treatment with biological drugs without a previous use of Methotrexate or Cyclosporine for at least 3 months. The Pso-Path Working Group concluded that it would be desirable to incentivize, through the formalization of regional guidelines, the creation of a network system that promotes not only a greater awareness, at the territorial level, of the importance and impact of the disease and the possible paths, but also the collaboration and connection between all the actors involved in the overall care of the patient VSports手机版. .
Keywords: Methotrexate; Posistion paper; Pso-Path Working Group; Psoriasis V体育安卓版. .
©Copyright: the Author(s).
Conflict of interest statement
Conflict of interest: The authors declare no potential conflict of interest.
References
-
- Prignano F, Rogai V, Cavallucci E, et al. . Epidemiology of Psoriasis and Psoriatic Arthritis in Italy-a Systematic Review. Curr Rheumatol Rep 2018;20:43. - PubMed
-
- Zagni E, Colombo D, Fiocchi M, et al. . Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Expert Rev Pharmacoecon Outcomes Res 2020;20: 491-7. - PubMed
-
- Multidisciplinary Working Group in Dermatology Emilia-Romagna Region. Systemic treatment of moderate-severe chronic plaque psoriasis with particular reference to biotechnological drugs. Therapeutic guideline no.1. Update May 2019 Assessorato Cura della persona, Salute e Welfare Regione Emilia- Romagna.
-
- IQVIA Holdings Inc. IQVIA data 2nd quarter 2020. Available from: https://s24.q4cdn.com/326377938/files/doc_news/2020/07/22/IQVIA-Q2-2020-...
-
- Agenzia Italiana del Farmaco. National Observatory for medicines use. National Report 2015. Rome: Agenzia Italiana del Farmaco, 2016.